The interaction of pyronin Y, an RNA intercalating drug, with the binding of Rev protein from human immunodeficiency virus type 1 (HIV-1) to Rev-responsive element (RRE)-containing en'{i'~NA was studied.
Introduction
The expression of the human immunodeficiency virus type 1 (HIV-1) genome starts with the production of short, fully-spliced =2-kb RNAs encoding the viral trans-acting regulatory proteins Tat, Rev, and Nef. The accumulation of the rev gene product then allows the synthesis of the unspliced, full-length =9-kb virion RNA, which expresses the structural proteins Gag and Pol, and of the singlyspliced =4-kb RNA, which codes for the structural protein Env as well as Vif, Vpr, Vpu and a shortened form of Tat (Rosen etal., 1988; Kim etal., 1989) . The HIV-1 Rev protein Received 30 April, 1992; revised 6 August, 1992. tFor is a 19-kDa nuclear phosphoprotein which appears to be localized mainly in the nucleolus of cells expressing HIV-1 (Cullen et al., 1988; Felber et el., 1989; Cochrane et al., 1990b) . Rev acts through binding to a cis-acting RNA sequence, called the Rev-responsive element (RRE) (Rosen et sl. 1988; Hadzopoulou-Cladaras et al., 1989; Malim et al., 1989; Daefler et el., 1990) . The RRE which is present in the 9-kb and 4-kb viral RNA is assumed to form a complex secondary structure (Malim et al., 1989; Cochrane et aI., 1990a; Kjems et al., 1991) . Rev protein most likely binds to a 'bubble' formed by an opposite GG and GUA bulge within the double-stranded segment of an RNA stem-loop near the 5' terminus of the RRE (Heaphy et el., 1991) . The mechanism through which Rev enhances the sequence-specific expression of unspliced and incompletely spliced HIV-1 mRNA (Feinberg et al., 1986; Sodroski et et., 1986; Emerman et al., 1989) is still a matter of controversy. Rev may promote the nuclear export of the RRE-containing structural mRNAs either by a direct interaction with the nucleocytoplasmic mRNA transport apparatus (Emerman et aI., 1989; Malim et sl., 1989; Pfeifer et al., 1991) or by blocking spliceosome assembly of HIV transcripts, thus permitting transport of the unspliced or incompletely spliced RNA to the cytoplasm (Chang and Sharp, 1989) . However, it has been shown that Rev can also act on mRNAs that lack functional splice sites (Rosen etsl., 1988; Emerman et al., 1989) . Increasing evidence suggests that the mode of action of Rev involves two steps: (1)binding of Rev to RRERNA, and (2)interaction of the Rev-RRE complex with cellular factor(s) involved in the processing and/or transport of HIV-1 mRNA (Cullen and Malim, 1991; Rosen, 1991) . Recently we could demonstrate in in vitro experiments (Pfeifer et sl., 1991) that Rev binds to a 11O-kDa nuclear-envelope protein, the putative mRNA carrier. Nuclear export of cellular poly(A)-rich RNA and the nuclear-envelope nucleoside triphosphatase activity mediating transport of poly(A)-rich mRNA (Schroder et al., 1986 (Schroder et al., , 1987 were strongly inhibited by Rev protein, whereas transport of RRE-containing viral env RNA was found to be increased.
The Rev-RRE complex appears to be a promising target for therapeutic intervention of HIV infection. Here we show that pyronin Y, an intercalating cationic dye that exhibits specificity towards RNA and condenses preferentially single-stranded RNA rather than DNA (Darzynkiewicz et al., 1986) , is able to inhibit the formation of the Rev-RRE
Results
complex. In addition we demonstrate that pyronin Y suppresses the RRE-nucleated assembly of Rev protein along RRE-containing RNA recently observed in electron microscopy (Heaphy et aI., 1991) . 
Anti~HIVactivity
In the cytoprotection assay (HTLV-lIl s-infected GEM cells), pyronin Y was.tested for anti-HIV-1 activity. The cell density was determined by the MTI assay. In contrast to its strong suppressive effect on Rev-RRE complex formation, pyronin Y exhibited a small cytoprotective effect on HIV-1-infected cells in vitro only after an incubation period of 5 days. As shown in Fig. 2A the viability of non-infected GEM cells was reduced to 50% at 0.64jLg rnr' of pyronin Y (equivalent to 2.1jLM after a 7-day incubation period). The cell viability in assays with HIV-1infected cells was not significantly increased and did not reach the 50% value of the non-infected controls. Also when pyronin Y was added to the cells after a 5-day Rev/assay (90nM) the migration of the RNA-protein complex was significantly slower (lane b). The latter result may indicate that at higher concentrations multimers of the Rev protein became associated with the same RNA molecule. The complex formation was strongly inhibited after addition of pyronin Y to the reaction mixture (lanes c, d, e, i, and D. In the presence of 1jLg mr' of pyronin Y (3.3jLM) and higher, complex formation was almost totally suppressed, both in assays containing 7.2 and 36 ng of Rev protein (lanes d, e, and D. The complex formation was also abolished after addition of a 10 or 200-fold excess of unlabelled competitor RRE RNA to the standard assay mixture (lanes f and g). No complex formation was observed with an antisense RRE transcript (same size), which is predicted to display also a highly-ordered secondary structure (lanes k and I). In a control experiment it was determined that the RRE RNA is not degraded by pyronin Y itself (Fig. 1S, lanes a and b) .
In order to determine the dissociation constant of the Rev-RRE complex nitrocellulose filter binding assays were performed. Evaluation of the binding data obtained in the presence of 200 mM NaGI in the standard assay mixture resulted in non-linear Scatchard plots, confirming previous results (not shown; see also Heaphy et al., 1991) . In the presence of lower salt concentrations (50 mM NaGI)the Scatchard plot was linear; under these conditions, a dissociation constant (KcJ of the Rev-RRE complex of 1.9 x 10-10 Mwas calculated using the LIGAND program. This value is consistent with that determined previously (Pfeifer et al., 1991) . The number of binding sites was determined to be 4.4 mol of Rev mol" of RRE transcript. The lower value measured previously (0.8 mol of Rev rnor' of RRE transcript) under similar conditions may be due to the different procedure used for purification of Rev protein in this study (Pfeifer et al., 1991) . We found in electron microscopical studies that Rev protein purified by electroelution from gels (Pfeifer et al., 1991) has a reduced ability to polymerize (not shown). 
Effect on Rev binding to RRE transcripts
For the binding studies, the factor X a cleavage product of a l3-galactosidase-Rev fusion protein was used (Pfeifer et al., 1991) . This Rev polypeptide, in the following termed recombinant Rev protein, was purified by chromatography on DEAE-Sepharose and heparin-Sepharose. The resultinq protein preparation was >95% pure and displayed a molecular mass of 18 kDa in SDS-polyacrylamide gels.
As shown in Fig. 1A , in gel retardation assay the recombinant Rev protein formed a band-shifted complex with an RRE transcript spanning from nt 7201 to 7567 (Ratner et al., 1985) . Non-specific binding of Rev to RRE was suppressed by addition of an 800-fold molar excess of tRNA to each assay. A mobility shift of the 32P-labelled RNA (lane a) was observed already at the low amount of 7.2ng (18nM) of Rev protein per assay (lane h); at this concentration almost all RRE transcripts had been converted to the RRE-Rev complex. However, at 36ng 'of Inhibition of Rev-RRE complex 105 A Fig. 2 . Effect of pyronin Yon viability of non-infected and HIV-1"infected CEM cells. In (A), treatment of cells with pyronin Y started 1 h after infection and continued for 7 days; and in (B), cells (non-infected and HIV-infected) were first incubated without pyronin Y for 5 days, and then in the presence of compound for 2 days. The number of viable cells was determined using the MTT assay system; the viability of the untreated. uninfected cells was set at 100%. (0) Uninfected cells; (e) HIV-1infected cells.
Effect on cell growth and viability
The cytostatic activity of pyronin Y was determined in the L5178y mouse lymphoma cell system. The cells were grown in the presence of 0.2-8.2 fL9 mr' of pyronin Y (equivalent to 0.6-27.3 fLM). Both the cell number and the cell viability were determined. Pyronin Y displayed a strong cytostatic activity. At a drug concentration of up to 1.6 fLM the growth rate was suppressed concentrationdependently without significant cell death (3-day incubation period). At higher concentrations (~2.5 fLM) the compound was toxic for the cells. At 2.5 fLM pyronin Y the cytotoxic effects became apparent on day 3 and at 8.2 fLM already after 1 day of treatment. The ED so concentration was calculated to be 1.3 fLM (0.39 fL9 ml-1 ) .
Effect on Rev oligomerization
In view of published results shoWingRev protein to be able to polymerize and to form filamentous ribonucleoprotein complexes along RRE-containing RNAs (Heaphy et al., 1991; Zapp at al., 1991) , we determined the effect of pyronin Y on RRE-nucleated Rev filament formation. Interaction of Rev with the RRE as an oligomer can be deduced from the results of gel-shift experiments (see above). The method of electron microscopy was used to demonstrate formation of oligomeric Rev-RRE complexes.
As shown in Fig. 3a , incubation of the 407-base RRE transcript with the recombinant Rev resulted in formation of short (up to 140nm in length) filaments. Much longer filaments (up to 1200 nm in length) were formed when the 2.4-kb envgene transcript was used as RRE-carrying RNA (Fig. 3c ). No filamentous structures could be observed when Rev-RRE complex formation was allowed to occur in the presence of 3 fLg mr' of pyronin Y ( Fig. 3b and d) . incubation period without compound, followed by a 2-day incubation in the presence of the drug, no cytoprotective effect was observed ( Fig. 2B ). Under these conditions the viability of non-infected cells was reduced to 50% at 3.7 fL9 rnl" of pyronin Y (equivalent to 12.2 fLM). However, at a shorter incubation period (5 days), a slight increase in viability of the cells became obvious (Table 1) ; at 0.1 fL9 mr' of pyronin Y, the percentage amount of viable cells was found to be increased from 31.0% to 47.4%.
In addition, the effect of pyronin Y on HIVreplication was measured using the HTLV-llIslH9 cell system by determination of the percentage of HIV-1 p24-positive cells. The number of positive cells amounted to 37% after an incubation period of untreated, infected cells for 5 days.
After treatment with 0.3 fLg mr' of pyronin Y, the number of positive cells was insighificantly reduced to 34%. At higher concentrations the compound was toxic for the cells. The uninfected cells did not express p24 antigen. 
Effect on viral RNA synthesis
Northern blot analysis of the RNA from HIV-infected CEM cells treated for 5 days with pyronin Y (1 f.Lg mr')showed a reduction of the amount of the =9 kb genome-length RNA and the incompletely spliced =4 kb RNA but not the =2 kb fully-spliced RNA (Fig. 4A, lane b) compared to the RNA from untreated cells (Fig. 4A, lane a) . At the same concentration, pyronin Y displayed no effect on the level of the cellular actin mRNA (Fig. 4B, lanes a and b) . This result indicates that pyronin Y may suppress the Rev-mediated enhancement of expression of the HIV structural mRNAs. The effect of pyronin Y on viral RNA synthesis was also studied in in vitro transcription experiments in isolated nuclei from HIV-1-infected H9 cells. The nuclei were preincubated in the absence or presence of 0.3 or 1 f.Lg mr' of pyronin Y and then incubated at the same drug concentration in a transcription assay containing [a-32 P]UTP as described in 'Materials and Experimental procedures'. In order to determine the relative amounts of tat-env-and gag-containing transcripts formed in the absence or presence of pyronin Y, equivalent amounts of the 32P-labelled transcripts were then hybridized to nitrocellulose-bound DNA spots carrying an excess of either tat-env, gag, or control pUC DNA (Fig. 5) . Incubation of the nuclei with upto 1 f.Lg rnl" of pyronin Ywas found to have no marked effect on synthesis of RNA hybridizing to tat-env DNA (containing sequences complementary to those present both in unspliced and fully spliced HIV mRNA) ( Fig. 5, upper panel) but strongly suppressed the synthesis of RNA hybridizing to gag DNA (Fig. 5, middle  panel) . No hybridization of the radiolabelled transcripts was observed with pUC control DNA (Fig. 5, lower panel) .
Discussion
In this study we show that the intercalating dye pyronin Y is able to inhibit the complex formation between the HIV-1 Rev protein and RRE-containing RNA. Binding of the recombinant Rev protein (factor X a cleavage product of a [3-galactosidase-Rev fusion protein) to RRE-containing RNA transcripts was demonstrated by using gel retardation assay procedure, similar as reported previously (Pfeifer et al., 1991) . Binding was found to be specific and was not abolished by a large excess of unlabelled RNA and not observed with an antisense RRE transcript, also predicted to have an extensive secondary structure. In nitrocellulose-filter-binding studies, an apparent I<tt of 1.9
x 10-10 M was determined for the Rev-RRE complex (see also Pfeifer et sl., 1991) ;this value is even smaller than that found for the Tat-TAR interaction [K d = 0.3 X 10-9 M (Muller et sl., 1990) ] and grossly agrees with those reported by others (Daly et aI., 1989; Heaphy et aI., 1990) . Formation of the Rev-RRE complex was totally abolished by pyronin Y already at a low drug concentration of 1 f.l.g ml".
The inhibitor, pyronin Y, has been shown to be an intercalating agent displaying high selectivity towards double-stranded RNA (Darzynkiewicz et el., 1986) . In addition, pyronin Y has been found to bind and condense single-stranded RNA; the most sensitive polymer to undergo condensation is poly(A).,Elbuble-stranded and single-stranded DNA are much more'resistant to conden-. sation. We assume that the suppression of complex formation between Rev protein and RRERNA by pyronin Y is caused by intercalation of the helical RNA segment of the RRE stem-loop that contains the Rev binding site and not by condensation of the single-stranded RNA segments within the RRERNAtranscripts. This conclusion has been drawn from the fact that condensation of single stranded RNA [with the exception of poly(A)] requires higher drug concentrations (;:,:45 fLM; Darzynkiewicz et et., 1986) than those applied to inhibit Rev-RRE interaction.
Despite its strong inhibitory effect on Rev-RREcomplex formation, pyronin Y did not exhibit a marked antiviral effect on HIV-1-infected H9 cells or a cytoprotective effect on HIV-1-infected CEM cells in vitro. In the L5178y mouse lymphoma cell system, pyronin Y displayed a strong cytostatic activity (ED so = 1.3 fLM). Nevertheless, treatment of HIV-infected CEM cells with 1 fL9 rnr' of pyrqnin Y was found to cause a decrease in the amount of unspliced 9-kb HIV RNA and singly-spliced 4-kb HIV RNA relative to fully-spliced 2-kb HIV RNA when compared to the RNA from untreated cells, indicating that Rev-mediated enhancement of expression of the HIV structural mRNAs is suppressed by this drug. The same conclusion can be drawn from the results of in vitro transcription experiments in isolated nuclei, showing that pyronin Y does not affect the synthesis of tat-en v RNA but strongly decreases the synthesis of gag RNA.
It was not surprising that pyronin Y is inactive in HIV-infected cells because it is known that the compound may also bind to DNA (Darzynkiewicz et el., 1986) .There is no evidence that the drug is transformed to an inactive Inhibition of Rev-RRE complex 107 metabolite inside the cell (Darzynkiewicz et al., 1986) . There are also no hints that the recombinant and endogenous Rev are functionally different (Aepinus et al., 1990; Pfeifer et al., 1991) . Moreover, it cannot be excluded that in vivo, in addition to Rev, other proteins bind to the RRE sequence which might modify the sensitivity of drug action on Rev-RRE complex formation.
From fluorescence microscopic studies it is known (Darzynkiewicz et al., 1986 ) that at lower concentrations which are not cytotoxic pyronin Y accumulates in mitochondria and is not present in the nucleus or cytoplasm where it might interact with Rev binding to the RRE sequence. At higher concentrations (;:':3.3 fLM) found to inhibit Rev-RRE interaction the drug is localized predominantly in the nucleoli and also in the cytoplasm where it could interfere with Rev-RRE complex formation. It might be interesting that Rev protein tends also to accumulate in the nucleolus (Cochrane et aI., 1990b) . At these concentrations pyronin Y is cytotoxic (Darzynkiewicz et al., 1986; and this study) .
It has been shown that initial binding of a Rev protein to a high-affinity site on the RRE most likely representing the purine-rich 'bubble' nucleates the assembly of additional Rev molecules to form long filamentous ribonucleoprotein structures which may be detected by electron microscopy (Heaphy et al., 1991) . Because the additional Rev molecules bind to the RRE RNA with lower affinity Scatchard plots for Rev binding to RRE RNA may be non-linear (Heaphy et aI., 1991) . Possibly Rev selectively inhibits spliceosome assembly of HIV mRNA by packaging the RRE-carryingviral transcripts into stable nucleoprotein complexes (Heaphy et aI., 1991) . We observed that during incubation of recombinant Rev protein with the 407-base RREtranscript short (up to 140 nm long) rod-like complexes are formed. Addition of Rev to the 2.4-kb env gene transcript resulted in the formation of longer filaments (up to 1200nm). No filaments were observed when pyronin Y was present in the incubation mixtures.
Although at present a direct application of the RNA intercalating dye, pyronin Y, in anti-HIV therapy cannot be envisaged due to its high cytotoxicity, this drug might be usable in combination therapy, e.g. together with immunomodulatory and antiviral double-stranded RNAs. Therefore, the inhibition of Rev-RREcomplex formation by pyronin Y may represent not only a new experimental approach to study Rev-RRE function but also a new strategy for inhibition of HIV replication possibly interesting for anti-HIV therapy.
Materials and Experimental procedures

Materials
The following materials were obtained. [a-3 2P]UTP (3DDDCi mmol "), and [a-3 2P]dTTP (3DDDCi mrnor') were from Amersham International PLC (Buckinghamshire, UK); anti-mouse IgG (peroxidase conjugated from rabbit), and (3-[4,5-dimethylthiazol-2-yl] -2,5-diphenyltetrazolium bromide (MTl) from Sigma (St. Louis, MO); T7 RNA polymerase, RNasin (RNase inhibitor), and the restriction enzymes from Boehringer Mannheim (Mannheim, Germany); and antibodies (polyclonal) to HIV-1 p24 from Biochrom (Berlin, Germany).
Pyronin Y (mol. wt. 302.8) was obtained from Sigma (St. Louis, MO) and purified to apparent homogeneity by extraction with CHCI 3 and crystallization from methanol as described by Darzynkiewicz et al. (1986) . The purity of the compound was checked by thin-layer chromatography (Silica Gel G) using normal butyl alcohol:formic acid (4:1, vol/vol) as solvent (Schweppe, 1969) . The concentration of the dye in solution was measured calorimetrically (molar extinction coefficient, E s4s = 1.03 x 1OSM-1 cm-1 ; MOiler and Crothers, 1975) .
Cells and virus infection
Human T lymphoblastoid CEM cells were grown in RPMI 1640 medium (Gibco, Karlsruhe, Germany) supplemented with 10% fetal calf serum. Cultures were maintained at 3rC in a humidified atmosphere at 5% CO 2 in air. Cells were routinely seeded at a concentration of 1 x 10 s cells rnr ' and infected with HIV-1 (strain HTLV IIIB ; Popovic et aI., 1984) at 50 50%-cell culture infective dose [CCID so ] (1 CCID so being the dose infective for 50% of the cell culture) per ml of cell suspension. One-millilitre cultures were incubated in the presence or absence of the test compound for up to 7 days. During that time, the uninfected CEM cells had undergone 2.05 doubling steps and the infected cells 0.16 doubling steps. The number of doubling steps was calculated as described (MOiler et al., 1975) . The number of viable cells was monitored using the MIT colorimetric assay system (Scudiero et al., 1988) and evaluated with an ELISA reader (Bio-Rad, model 35.50, equipped with the program NCIMR IIIB) (Renneisen et al., 1990; MOiler et al., 1991) . The absorbances measured in control assays (without MTl) containing the respective pyronin Y concentrations were subtracted.
H9 human T-cells were maintained in RPMI-1640 medium containing 15% fetal calf serum at 37°C in a humidified 5% CO 2 in air atmosphere. The cells (5 x 10 4 ; in t-ml assays) were infected with 5 x 10 6 HTLV IIIB particles and cultivated for up to 5 days in the absence or presence of pyronin Y (Sarin et al., 1987) . The percentage of cells expressing p24 gag protein of HIV-1 was determined by indirect immunofluorescence microscopy with the use of mouse monoclonal antibodies to HIV-1 p24 (Sarin et al., 1987; Schroder et al., 1989b) . The positive cells were visualized by treatment with fluorescein-labelled goat anti-mouse IgG.
Pyronin Y was dissolved in dimethyl sulphoxide at a stock concentration of 2 mM; it was added at a final concentration of 0.00254 to 50 f.Lg rnr ' 1 h after addition of the virus (= day 0)to the uninfected or infected cultures. Alternatively, pyronin Y was added to the HIV-infected or uninfected cells (CEM cells) after a 5-day incubation period without compound; the cells were then incubated in the presence of compound for 2 days. The final concentration of dimethyl sulphoxide was less than 0.1%.
Cell growth inhibition studies
L5178y mouse lymphoma cells were grown in Eagle's rnlnlrnum essential medium supplemented with 10% horse serum in roller tube cultures (MOiler and Zahn, 1979; MOiler et al., 1983) . Dose response experiments were performed as described (MOiler et al., 1983) . The cell concentration was determined electronically (Cytocomp Counter, model Michaelis) . The effective dose, which inhibits cell proliferation by 50% (ED so ) was estimated by logarithmic regression (Sachs, 1974) .
Plasmid constructs and in vitro transcription
The RRE-containing envfragment of HIV-1 (nt 7201 [BgIII site] to 7567 [Sau3A site]; according to Ratner et el., 1985) was excised from lambdaBH10 (Hahn et al., 1984) , filled-in by DNA polymerase I (Klenow fragment) and blunt-end ligated into the Hincll-cut and dephosphorylated vector pGEM-4Z (Promega) downstream of the T7 promoter. The orientation of the inserted fragment was ensured by double digestion. Sense and antisense RNAs (407 base long) were synthesized in vitro using [a-32P]UTP and T7 RNA polymerase after linearization of the plasmid DNA at the unique Xba I site. Reactions were terminated by DNase digestion followed by phenol-chloroform extraction. The 2.4-kb envDNA of HIV-1 (nt 5789 [EcoRI site] to 8183 [Hindlll site]) carrying the RRE sequence was inserted between the EcoRI and Hindlll sites of pGEM-1 (Promega). For in vitro transcription with T7 RNA polymerase the plasmid was digested with Hindll!. The specific radioactivities of the labelled transcripts were 5--6 c.p.m. pmol-1 nucleotide incorporated.
The gag-containing HIV-1 fragment (nt 229 [Sacl site] to 1643 [BgIII site]) was inserted into pUC8 and termed pUC8GAG (MOiler et al., 1990) .
In vitro synthesis of Rev protein
Rev was expressed as a fusion protein with E. coli l3-galactosidase and purified as described (Aepinus et al., 1990) . Rev-peptide was obtained through cleavage of the fusion protein with factor X a (Boehringer Mannheim) (Pfeifer et al., 1991) and subsequently purified by ion exchange chromatography on DEAE-Sepharose CL-6B and affinity chromatography on heparln-Sepharose as described (Zapp et al., 1991) . The molecular mass of the purified Rev was t8kDa (Pfeifer et al., 1991) .
Gel retardation assay
The 32P-labelled RNA was incubated in a final reaction volume of 20 f.L1 with various amounts of recombinant Rev protein, in a 10 mM Hepes buffer (pH 7.6, 10% glycerol, 50mM NaCI, 2mM MgCI 2 , 0.5mM EGTA, 1 mM dithiothreitol, 7.5f.Lg rnr' bovine serum albumin), supplemented with 100ng of E. coli tRNA and 20U RNasin/assay (Malim et al., 1990; Pfeifer et al., 1991) . After an incubation period of 20 min at 22°C, 1 ul of bromophenol blue dye was added, and the samples were loaded on a non-denaturing 6% polyacrylamide gel (acrylamide to bisacrylamide ratio of 38:1) containing TBE (= 90mM Tris-borate pH 8.3, 2mM EDTA) buffer and 5% glycerol. Electrophoresis was performed at 7.5mA at room temperature until the bromophenol blue dye had migrated a distance of approximately 10cm. The wet gels were blotted to Whatman No. 3MM chromatographic paper, dried, and autoradiographed.
Nitrocellulose filter binding assay
The filter binding assays were performed as described previously (Pfeifer et al., 1991) with the following modifications. Each assay contained in a final volume of 40 fLl, 2 pmol of recombinant Rev and 0.02-10 pmol of 32P-labelled sense RRE RNA in the binding buffer (10mM Tris-HCI pH 7.5, 1 mM MgCI 2, 50fLg rnr ' bovine serum albumin), supplemented either with 50mM NaCI or200mM NaCI, together with 40 U RNasin and 1 fL9 of carrier tRNA (E. coli). The reaction mixtures were incubated for 20 min at 22°C. The samples were then applied onto nitrocellulose filter (Millipore HAWP; 0.45 urn). After washing with binding buffer containing 1% dimethyl sulphoxide, filter-bound radioactivity was defermined. The binding data were determined by Scatchard analysis using the LIGAND program (Munson and Rodbard, 1980) .
Formation of Rev filaments
Oligomerization of Rev protein along RRE-containing RNA in the absence or presence of pyronin Y was carried out as described by Heaphy et al. (1991) . In brief, ribonucleoprotein filaments consisting of RRE-containing RNA and oligomerized Rev were prepared from in vitro transcribed 407-base long~RE RNA or 2.4-kb env-RNA carrying the RRE sequence (fiJi~1 concentrations, 90 and 70-80 ng mr' ,resp.) and recombinaijiRev protein (40-50 fL9 mr ') in 20mM Tris-HCI pH 7.4, containing 50mM NaCl, 0.1 mM EDTA, 1 mM dithiothreitol and 20 U rnl" of RNasin; incubation was done at 30°C for 1 h. Complexes formed were inspected by electron microscopy.
Northern blot hybridization
RNA was isolated as described (Chirgwin et al., 1979) . Poly(A)rich RNA was selected by binding to poly(U) filter. Electrophoresis of the denatured RNA samples on 1.3% agarose gels containing 2% formaldehyde, blot-transfer to nitrocellulose and hybridization to the 32P-labelled DNA probes were performed as described previously . The tat-env fragment [nt 5327 (EcoRI site) to 6250 (AhaIII site)] was cloned into pGEM-4Z vector and termed pGEMTAT-ENV. The human l3-actin DNA probe was prepared from plasmid pHf13A-1 and cloned into pBR322 (Gunning et al., 1983) . The DNA probes were labelled by nick-translation with [ct-32 P]dTTP to a specific radioactivity of 7-8 x 10 7 c.p.m, fL9-1 of DNA. Dried nitrocellulose filters were exposed to Kodak XAR-5 X-ray film backed by one intensifying screen for 24 h at -70°C.
Transcription in isolated nuclei
The in vitro transcription in isolated nuclei was performed essentially as described previously (MOiler et el., 1990) . In brief, nuclei were isolated from HTLVIIIB-infectedH9 cells 3 days p.i. as described (Blobel and Potter, 1966) . The nuclei (10 6 per 100-fLl assay) were then pre-incubated for 15 min at 4°C in the absence or presence of pyronin Y. Subsequently 500 fLM each of ATP, GTP, and CTP, and 100 fLM [ct-32 p]UTP (1000 u.Ciml-1 ) was added to a final assay volume of 0.5 ml and incubation was continued at 25°C for 30 min in the absence or presence of the drug. The 32P"labelied RNA was then extracted and hybridized to 5 fL9 of Inhibition of Rev-RRE complex 109 tat-env DNA (pGEMTAT-ENV), gag DNA (pUC8GAG), and pUC DNA immobilized on nitrocellulose (MOileret el., 1990) .
Electron microscopy
Rev filaments were negatively stained with uranyl acetate and examined in a Zeiss EM 9A electron microscope.
